Cargando…

BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma

BACKGROUND: Although gene expression profile of multiple myeloma (MM) patients shows a wide range of Bik/Nbk expression, varying from absent to high, its regulation and function in myeloma cells is poorly understood. Thus, we addressed these questions in MM. METHODS: Human myeloma cell lines (HMCLs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bodet, L, Ménoret, E, Descamps, G, Pellat-Deceunynck, C, Bataille, R, Le Gouill, S, Moreau, P, Amiot, M, Gomez-Bougie, P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008608/ https://www.ncbi.nlm.nih.gov/pubmed/21063407 http://dx.doi.org/10.1038/sj.bjc.6605981

Ejemplares similares

The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction
por: Descamps, G, et al.
Publicado: (2012)

Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma
por: Maïga, S, et al.
Publicado: (2013)

Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK
por: Brosseau, C, et al.
Publicado: (2014)

Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells
por: Chiron, D, et al.
Publicado: (2013)

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways
por: Tessoulin, Benoît, et al.
Publicado: (2018)

Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma
por: Kervoëlen, Charlotte, et al.
Publicado: (2015)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease
por: Lodé, L, et al.
Publicado: (2013)

BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells
por: Butterworth, Michael, et al.
Publicado: (2016)

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53(abnormal) myeloma cells independently of the p53 pathway
por: Surget, Sylvanie, et al.
Publicado: (2014)

Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups
por: Gomez-Bougie, Patricia, et al.
Publicado: (2014)

A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
por: Descamps, G, et al.
Publicado: (2009)

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells
por: Gillardin, Pierre-Samuel, et al.
Publicado: (2017)

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
por: Seiller, Carolane, et al.
Publicado: (2020)

Targeting Oxidative Stress With Auranofin or Prima-1(Met) to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells
por: Tessoulin, Benoit, et al.
Publicado: (2019)

BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics
por: Touzeau, Cyrille, et al.
Publicado: (2015)

Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents
por: Saha, M N, et al.
Publicado: (2014)

Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib
por: Sanchez, W Y, et al.
Publicado: (2013)

Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells
por: Suman, S, et al.
Publicado: (2013)

Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells
por: Saito, T, et al.
Publicado: (2008)

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma
por: Benaniba, Lina, et al.
Publicado: (2019)

PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells
por: Maginn, E N, et al.
Publicado: (2011)

Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
por: Caers, J, et al.
Publicado: (2008)

Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells
por: Amit-Vazina, M, et al.
Publicado: (2005)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
por: Chiron, David, et al.
Publicado: (2015)

BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker
por: Tessoulin, Benoît, et al.
Publicado: (2019)

Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos
por: Farnoushi, Y, et al.
Publicado: (2011)

Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2018)

Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa
por: de Bruijn, M T, et al.
Publicado: (2010)

Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model
por: Delord, J-P, et al.
Publicado: (2010)

Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane
por: Maloney, S L, et al.
Publicado: (2009)

Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo
por: Weiss, C, et al.
Publicado: (2012)

The pro-apoptotic paradox: the BH3-only protein Bcl-2 interacting killer (Bik) is prognostic for unfavorable outcomes in breast cancer
por: Pandya, Vrajesh, et al.
Publicado: (2016)

Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma
por: Cheriyath, V, et al.
Publicado: (2011)

Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress
por: Ketola, K, et al.
Publicado: (2012)

An anti-leishmanial thiadiazine agent induces multiple myeloma cell apoptosis by suppressing the nuclear factor kappaB signalling pathway
por: Chen, G, et al.
Publicado: (2014)

Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis
por: Bustany, Sophie, et al.
Publicado: (2015)

Antitumour effect of polyoxomolybdates: induction of apoptotic cell death and autophagy in in vitro and in vivo models
por: Ogata, A, et al.
Publicado: (2008)

The role of glucocorticoids in the induction of zinc-α(2)-glycoprotein expression in adipose tissue in cancer cachexia
por: Russell, S T, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_salm32nq3efidbvgegop524jjk